Literature DB >> 31273344

Targeted resequencing of FECH locus reveals that a novel deep intronic pathogenic variant and eQTLs may cause erythropoietic protoporphyria (EPP) through a methylation-dependent mechanism.

Matteo Chiara1, Elena Di Pierro2, Ilaria Primon3, Letizia Tarantini4, Luca Agnelli5, Valentina Brancaleoni3, Francesca Granata3, Valentina Bollati4.   

Abstract

PURPOSE: Existing data do not explain the reason why some individuals homozygous for the hypomorphic FECH allele develop erythropoietic protoporphyria (EPP) while the majority are completely asymptomatic. This study aims to identify novel possible genetic variants contributing to this variable phenotype.
METHODS: High-throughput resequencing of the FECH gene, qualitative analysis of RNA, and quantitative DNA methylation examination were performed on a cohort of 72 subjects.
RESULTS: A novel deep intronic variant was found in four homozygous carriers developing a clinically overt disease. We demonstrate that this genetic variant leads to the insertion of a pseudo-exon containing a stop codon in the mature FECH transcript by the abolition of an exonic splicing silencer site and the concurrent institution of a new methylated CpG dinucleotide. Moreover, we show that the hypomorphic FECH allele is linked to a single haplotype of about 20 kb in size that encompasses three noncoding variants that were previously associated with expression quantitative trait loci (eQTLs).
CONCLUSION: This study confirms that intronic variants could explain the variability in the clinical manifestations of EPP. Moreover, it supports the hypothesis that the control of the FECH gene expression can be mediated through a methylation-dependent modulation of the precursor messenger RNA (pre-mRNA) splicing pattern.

Entities:  

Keywords:  CpG sites; deep intronic pathogenic variant; eQTLs; erythropoietic protoporphyria; pre-mRNA splicing pattern

Mesh:

Substances:

Year:  2019        PMID: 31273344     DOI: 10.1038/s41436-019-0584-0

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  1 in total

1.  A novel large deletion and three polymorphisms in the FECH gene associated with erythropoietic protoporphyria.

Authors:  Chumei Li; Elena Di Pierro; Valentina Brancaleoni; Maria Domenica Cappellini; David P Steensma
Journal:  Clin Chem Lab Med       Date:  2009       Impact factor: 3.694

  1 in total
  4 in total

1.  Genomic analyses of 10,376 individuals in the Westlake BioBank for Chinese (WBBC) pilot project.

Authors:  Pei-Kuan Cong; Wei-Yang Bai; Jin-Chen Li; Meng-Yuan Yang; Saber Khederzadeh; Si-Rui Gai; Nan Li; Yu-Heng Liu; Shi-Hui Yu; Wei-Wei Zhao; Jun-Quan Liu; Yi Sun; Xiao-Wei Zhu; Pian-Pian Zhao; Jiang-Wei Xia; Peng-Lin Guan; Yu Qian; Jian-Guo Tao; Lin Xu; Geng Tian; Ping-Yu Wang; Shu-Yang Xie; Mo-Chang Qiu; Ke-Qi Liu; Bei-Sha Tang; Hou-Feng Zheng
Journal:  Nat Commun       Date:  2022-05-26       Impact factor: 17.694

2.  Microcytosis in Erythropoietic Protoporphyria.

Authors:  Giovanna Graziadei; Lorena Duca; Francesca Granata; Giacomo De Luca; Anna De Giovanni; Valentina Brancaleoni; Isabella Nava; Elena Di Pierro
Journal:  Front Physiol       Date:  2022-03-03       Impact factor: 4.566

Review 3.  Recognized and Emerging Features of Erythropoietic and X-Linked Protoporphyria.

Authors:  Elena Di Pierro; Francesca Granata; Michele De Canio; Mariateresa Rossi; Andrea Ricci; Matteo Marcacci; Giacomo De Luca; Luisa Sarno; Luca Barbieri; Paolo Ventura; Giovanna Graziadei
Journal:  Diagnostics (Basel)       Date:  2022-01-08

4.  Ultraviolet A phototest positivity is associated with higher free erythrocyte protoporphyrin IX concentration and lower transferrin saturation values in erythropoietic protoporphyria.

Authors:  Giovanni Genovese; Carlo Alberto Maronese; Chiara Moltrasio; Roberta Piccinno; Dario Antonio Marletta; Giacomo De Luca; Giovanna Graziadei; Francesca Granata; Elena Di Pierro; Maria Domenica Cappellini; Angelo Valerio Marzano
Journal:  Photodermatol Photoimmunol Photomed       Date:  2021-08-30       Impact factor: 3.254

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.